Need professional-grade analysis? Visit stockanalysis.com
$171.62M
58.53
N/A
N/A
Protalix Biotherapeutics Inc (PLX) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $2.20, down 0.90% from the previous close.
Over the past year, PLX has traded between a low of $1.35 and a high of $3.15. The stock has lost 25.2% over this period. It is currently 30.2% below its 52-week high.
Protalix Biotherapeutics Inc has a market capitalization of $171.62M, with a price-to-earnings ratio of 58.53.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Side-by-side comparison against top Healthcare peers.